# Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

> **NCT02800486** · PHASE2 · RECRUITING · sponsor: **Northwell Health** · enrollment: 37 (estimated)

## Conditions studied

- Glioblastoma
- Anaplastic Astrocytoma
- Anaplastic Oligoastrocytoma
- Glioma
- Brain Neoplasm
- Brain Cancer
- Brain Tumor
- Brain Tumor, Recurrent
- Brain Neoplasm, Malignant

## Interventions

- **DRUG:** Intra-arterial Cetuximab
- **DRUG:** Intra-arterial Mannitol
- **RADIATION:** Hypofractionated re-irradiation

## Key facts

- **NCT ID:** NCT02800486
- **Lead sponsor:** Northwell Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2016-05
- **Primary completion:** 2035-05
- **Final completion:** 2036-05
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02800486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02800486, "Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02800486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*